MIM
KLRS

MetLife Investment Management’s Kalaris Therapeutics KLRS Stock Holding History

MetLife Investment Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-927
Closed -$45.8K – 2870
2023
Q3 		$45.8K Hold
927
– – ﹤0.01% 2838
2023
Q2 		$72.5K Buy
927
+200
+28% +$19K ﹤0.01% 2839
2023
Q1 		$65.8K Hold
727
– – ﹤0.01% 2684
2022
Q4 		$85.7K Hold
727
– – ﹤0.01% 2650
2022
Q3 		$132K Buy
+727
New +$113K ﹤0.01% 2541
2022
Q2 		– Sell
-785
Closed -$122K – 2915
2022
Q1 		$122K Buy
785
+267
+52% +$53.3K ﹤0.01% 2587
2021
Q4 		$154K Hold
518
– – ﹤0.01% 2212
2021
Q3 		$299K Hold
518
– – ﹤0.01% 1823
2021
Q2 		$235K Hold
518
– – ﹤0.01% 2050
2021
Q1 		$279K Buy
518
+169
+48% +$142K ﹤0.01% 1858
2020
Q4 		$308K Hold
349
– – ﹤0.01% 1755
2020
Q3 		$221K Buy
+349
New +$238K ﹤0.01% 1803

Other funds holding KLRS

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

MetLife Investment Management's KLRS Position: Q4 2023 in Review

MetLife Investment Management sold out of Kalaris Therapeutics (KLRS) in Q4 2023, closing a stake of 927 shares — an estimated $45.8K sold.

MetLife Investment Management first reported a position in KLRS in Q3 2020 and held it in 12 quarters. The position peaked at $308K in Q4 2020. 81 funds tracked by Wall St. Rank hold KLRS as of Q4 2023.

  • MetLife Investment Management reported no remaining Kalaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • MetLife Investment Management sold 927 Kalaris Therapeutics shares in Q4 2023, an estimated $45.8K.
  • MetLife Investment Management first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 12 quarters.
  • MetLife Investment Management's Kalaris Therapeutics position peaked at $308K in Q4 2020.
  • 81 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2023.

Based on MetLife Investment Management's 13F filing for Q4 2023, filed 14 Feb 2024.